BioCentury on BioBusiness,
Fielding armies of antibodies
Monday, July 10, 2000
MorphoSys AG believes that the company that can produce human antibodies in the largest numbers will prevail in the battle to supply antibodies to partners. MorphoSys (NMarkt:MOR) is advancing that goal through a deal with DuPont Pharmaceuticals Co. to develop AutoCAL, a robotic system to screen, clone and analyze MOR's HuCAL antibody library.
MorphoSys (Munich, Germany) also believes that the automation technology will free up resources to address investor criticisms that the company has fallen behind its competitors in the development of an in-house pipeline of therapeutic candidates. According to CEO Simon Moroney, an undetermined number of staff will be freed up by AutoCAL to work on drug discovery for MOR's own account.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]